Kyowa Kirin Co., Ltd. (TYO:4151)
Japan · Delayed Price · Currency is JPY 2,403.50
-26.50 (-1.09%)
Sep 4, 2026, 3:30 PM JST
Kyowa Kirin Earnings Call Transcripts
Fiscal Year 2025
-
Revenue and profits declined year-over-year due to restructuring and special retirement costs, but key products like Crysvita and Poteligeo showed strong growth in North America and EMEA. R&D pipeline advanced with promising data for Ziftomenib and Rocatinlimab, and AI-driven strategies are boosting market penetration.
Fiscal Year 2024
-
A strategic partnership was formed to accelerate the global development and commercialization of ziftomenib, focusing on hematologic malignancies and solid tumors. The collaboration includes significant financial milestones, shared operational roles, and aims to position ziftomenib as a market leader, with pivotal trials and data updates planned in the near term.